关于公司参与福建省第四批药品集中带量采购拟中 选的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 | | --- | | 虚假记载、误导性陈述或重大遗漏。 | 近日，浙江佐力药业股份有限公司（以下简称"公司"）参与了福建省第四 批药品集中带量采购工作，根据福建省医疗保障局于 2023 年 12 月 19 日发布的 《福建省第四批药品集中带量采购公告（第 10 号）》显示，公司产品乌灵胶囊 拟中选本次集中带量采购，现将相关拟中选情况公告如下： 证券代码：300181 证券简称：佐力药业 公告编号：2023-052 浙江佐力药业股份有限公司 1 药品名称 适应症 剂型 规格 包装 拟中选价 计价单位 乌灵胶囊 补肾健脑，养心安 神。用于心肾不 交所致的失眠、健 忘、心悸心烦、神 疲乏力、腰膝酸 软、头晕耳鸣、少 气懒言、脉细或沉 无力；神经衰弱见 上述证候者。 胶囊剂 0.33g 0.33g×54 粒/盒 46.27 元 盒 一、拟中选产品基本情况 二、本次拟中选对公司的影响 本次拟中选产品乌灵胶囊为国家基药目录产品，乌灵胶囊于 2022 年度在福 建省的销售量占全国销量的 1.64%。 ...

证券代码：300181 证券简称：佐力药业 公告编号：2023-051 公司将根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关规定，尽快聘 任符合任职资格的人员担任证券事务代表。 特此公告。 浙江佐力药业股份有限公司 董 事 会 2023 年 12 月 22 日 1 浙江佐力药业股份有限公司 关于证券事务代表辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"）董事会于近日收到公司证 券事务代表周敏女士提交的书面辞职报告，其因个人原因申请辞去公司证券事务 代表职务，辞职报告自送达公司董事会之日起生效。周敏女士辞职后将不再担任 公司任何职务，其辞职不会影响公司相关工作的正常开展。 截至本公告日，周敏女士未持有公司股份，亦不存在应当履行而未履行的承 诺事项。周敏女士在任职期间恪尽职守、勤勉尽责，公司及公司董事会对其在任 职期间为公司发展所做出的贡献表示衷心感谢！ ...

公 告 证券代码：300181 证券简称：佐力药业 公告编号：2023-050 浙江佐力药业股份有限公司 关于使用部分闲置募集资金进行现金管理的进展 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"或"本公司"）于 2023 年 3 月 14 日召开了第七届董事会第十四次（临时）会议、第七届监事会第十二次 （临时）会议，审议通过了《关于使用部分闲置募集资金和闲置自有资金进行现 金管理的议案》，同意公司使用额度不超过人民币 30,000 万元（含本数）的闲 置募集资金和不超过人民币 20,000 万元（含本数）的闲置自有资金进行现金管 理，现金管理有效期自董事会审议通过之日起 12 个月内有效，在上述额度及有 效期内，资金可以循环滚动使用。同时，授权董事长在额度范围内行使该项投资 决策权并签署相关文件，公司财务部门组织实施。该授权自董事会审议通过之日 起 12 个月内有效。上述具体内容详见公司于 2023 年 3 月 14 日在巨潮资讯网披 露的《关于使用部分闲置募集资金和闲置自有资金进行现金管理的公告》（公告 编号：2 ...

证券代码：300181 证券简称：佐力药业 公告编号：2023-049 浙江佐力药业股份有限公司 关于控股子公司参与浙江省公立医疗机构第四批 药品集中带量采购拟中选的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，浙江佐力药业股份有限公司（以下简称"公司"）控股子公司青海珠 峰冬虫夏草药业有限公司（以下简称"珠峰药业"）参与了浙江省公立医疗机构 第四批药品集中带量采购工作，根据浙江省药械采购平台于 2023 年 11 月 17 日 发布的《浙江省药品医用耗材集中带量采购办公室关于浙江省公立医疗机构第四 批药品集中带量采购拟中选结果的公告》显示，公司控股子公司珠峰药业产品百 令片拟中选本次集中带量采购，现将相关拟中选情况公告如下： 注：上述产品的采购数量以浙江省药械采购平台发布的最终数据及控股子公司珠峰药业 后续签订的相关采购协议为准。根据浙江省公立医疗机构第四批药品集中带量采购文件（采 购文号 ZJYPCG-2023-1）的要求：（一）采购周期为 24 个月。如需延长采购周期，在采购 周期结束前另行公告。（二）采购周期内采购协议每年一签。续签采购协 ...

证券代码：300181 证券简称：佐力药业 公告编号：2023-048 浙江佐力药业股份有限公司 关于使用部分闲置募集资金进行现金管理的进展 公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"或"本公司"）于 2023 年 3 月 14 日召开了第七届董事会第十四次（临时）会议、第七届监事会第十二次 （临时）会议，审议通过了《关于使用部分闲置募集资金和闲置自有资金进行现 金管理的议案》，同意公司使用额度不超过人民币 30,000 万元（含本数）的闲 置募集资金和不超过人民币 20,000 万元（含本数）的闲置自有资金进行现金管 理，现金管理有效期自董事会审议通过之日起 12 个月内有效，在上述额度及有 效期内，资金可以循环滚动使用。同时，授权董事长在额度范围内行使该项投资 决策权并签署相关文件，公司财务部门组织实施。该授权自董事会审议通过之日 起 12 个月内有效。上述具体内容详见公司于 2023 年 3 月 14 日在巨潮资讯网披 露的《关于使用部分闲置募集资金和闲置自有资金进行现金管理的公告》（公告 编号：2 ...

证券代码：300181 证券简称：佐力药业 公告编号：2023-046 浙江佐力药业股份有限公司 二、对外担保进展情况 鉴于公司与中信银行西宁分行于 2023 年 1 月 9 日签署的《最高额保证合同》 已到期且执行完毕。近日，公司与中信银行西宁分行签署了《最高额保证合同》， 同意公司为珠峰药业向中信银行西宁分行申请2,000万元人民币的授信额度（敞口） 提供连带责任保证担保。上述担保属于已审议通过的担保事项范围，无需再次提交 董事会审议。 三、担保协议的主要内容 1、保证人：浙江佐力药业股份有限公司 2、债权人：中信银行股份有限公司西宁分行 关于为控股子公司向银行申请授信额度提供担保的 进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 浙江佐力药业股份有限公司（以下简称"公司"）于 2022 年 10 月 24 日召开 了第七届董事会第十二次会议、第七届监事会第十次会议，审议通过了《关于调整 控股子公司担保额度及期限的议案》，同意公司对青海珠峰冬虫夏草药业有限公司 （以下简称"珠峰药业"）向银行申请授信担保额度及期限做出相应调整，其 ...

证券代码：300181 证券简称：佐力药业 公告编号：2023-047 浙江佐力药业股份有限公司 关于公司及控股子公司参与江苏省第四轮药品集中 带量采购拟中选的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，浙江佐力药业股份有限公司（以下简称"公司"）及控股子公司青海 珠峰冬虫夏草药业有限公司（以下简称"珠峰药业"）参与了江苏省第四轮药品 集中带量采购工作，根据江苏省医疗保障局于 2023 年 11 月 9 日发布的《江苏 省第四轮药品集中带量采购公告（四）》显示，公司产品乌灵胶囊、珠峰药业产 品百令片拟中选本次集中带量采购，现将相关拟中选情况公告如下： 注：上述产品的采购数量以江苏省医疗保障局发布的最终数据及公司和控股子公司后续 签订的相关采购协议为准。根据江苏省医疗保障局发布的《江苏省第四轮药品集中带量采购 1 产品名称 适应症 剂型 规格 转换 比 包装 单位 包装 材料 备注 乌灵胶囊 补肾健脑，养心安 神。用于心肾不 交 所 致 的 失眠、健 忘、心悸心烦、神疲 乏力、腰膝酸软、头 晕耳鸣、少气懒言、 脉细或沉无力；神经 衰弱见上述证候者 ...

证券代码：300181 证券简称：佐力药业 编号：2023-011 浙江佐力药业股份有限公司 投资者关系活动记录表 投资者关系活 □特定对象调研 □分析师会议 动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动  现场参观  其他 （线上会议） 参与单位名称 2023 年 10月31 日：银华基金：吴颖；猎户星投研：梁挺； 及人员姓名 杭州象树资产：相迎；宁波量力资本：林杰、叶倩羲；华创 证券：董致君；深圳望正资产：高敏。 2023 年 11 月 1 日：东吴医药：朱国广；富国基金：于洋、 张啸伟、赵伟、韩雪、李淼、吴畏。 时间 2023 年 10月31 日10:30-11:30 2023 年 11月1 日 9:30-10:00 地点 现场会议、线上会议 ...

Financial Performance - The company's revenue for Q3 2023 was CNY 453,488,563.91, representing a 0.90% increase year-over-year, while the year-to-date revenue reached CNY 1,464,947,132.50, up 8.97% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was CNY 89,203,600.05, a 29.14% increase year-over-year, and the year-to-date net profit was CNY 286,865,191.49, reflecting a 40.65% growth[4] - The basic earnings per share for Q3 2023 was CNY 0.1272, up 12.07% year-over-year, with a year-to-date diluted earnings per share of CNY 0.4090, an increase of 22.05%[4] - Total operating revenue for the period reached CNY 1,464,947,132.50, an increase of 8.95% compared to CNY 1,344,402,602.13 in the previous period[18] - Net profit for the period was CNY 292,583,698.54, representing a 36.3% increase from CNY 214,596,952.02 in the previous period[20] - Basic and diluted earnings per share increased to CNY 0.4090 from CNY 0.3351, reflecting a growth of approximately 22%[21] Assets and Liabilities - The company's total assets at the end of Q3 2023 were CNY 3,543,470,789.72, a decrease of 2.63% from the end of the previous year[4] - The company's total assets decreased to CNY 3,543,470,789.72 from CNY 3,639,117,963.07, indicating a reduction in asset base[17] - Total liabilities decreased to CNY 830,182,267.56 from CNY 879,192,754.90, showing a decline in overall liabilities[17] - The total number of common shareholders was 40,247, with the largest shareholder holding 18.52% of the shares[13] - The total equity attributable to shareholders of the parent company was CNY 2,667,380,677.87, slightly down from CNY 2,703,749,664.26, indicating a minor decrease in shareholder equity[17] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 223,951,981.61, showing a 15.50% increase compared to the previous year[4] - The net cash inflow from operating activities was CNY 223.95 million, an increase of CNY 30.05 million or 15.50% year-on-year, primarily due to the growth in net profit and operating cash inflows[10] - Cash inflow from operating activities reached CNY 1,634,268,265.69, up from CNY 1,358,686,568.10, indicating a growth of about 20%[21] - The net cash flow from operating activities was CNY 223,951,981.61, compared to CNY 193,904,381.17 in the previous period, representing an increase of approximately 15.5%[21] - The net cash outflow from investing activities was CNY 115.15 million, an increase of CNY 52.45 million or 83.66% year-on-year, mainly due to a decrease in net cash inflow from investment products and an increase in long-term asset investments[10] - Cash outflow from investing activities totaled CNY 156,183,883.94, down from CNY 356,584,246.43, showing a reduction of about 56%[22] - The net cash flow from investing activities was -CNY 115,148,365.94, worsening from -CNY 62,695,018.67 in the previous period[22] - The net cash outflow from financing activities was CNY 170.68 million, an increase of CNY 4.61 million or 2.78% year-on-year, primarily due to increased dividend distributions and short-term borrowings[10] - The net cash flow from financing activities was -CNY 170,678,901.88, slightly worsening from -CNY 166,066,812.99 in the previous period[22] Investments and Projects - The company reported a significant increase in construction in progress, which rose to CNY 149,094,700, an increase of 91.01% due to ongoing investments in new projects[7] - The company plans to continue investing in the "Intelligent Traditional Chinese Medicine Production Base Construction and Upgrade Project" and the "Innovative Pharmaceutical Industrialization Project" to enhance its market position[8] - Research and development expenses increased to CNY 58,183,284.31 from CNY 50,502,876.94, highlighting ongoing investment in innovation[18] Other Financial Metrics - The company's cash and cash equivalents were CNY 1,010.08 million, down from CNY 1,082.07 million at the beginning of the year[15] - Accounts receivable increased to CNY 461.29 million from CNY 452.84 million at the beginning of the year[15] - Inventory increased significantly to CNY 400.31 million from CNY 318.83 million at the beginning of the year[15] - The company reported a financial income of CNY 17,342,268.01, significantly higher than CNY 1,791,225.26 in the previous period, indicating improved financial management[18] - Other comprehensive income after tax was reported at CNY -121,960,107.00, compared to CNY -264,556,940.89, reflecting a reduction in losses from other comprehensive income[20] - The report for the third quarter was not audited, indicating that the figures are preliminary and subject to change[23]

Financial Performance - The company's revenue for Q3 2023 was ¥453,488,563.91, an increase of 0.90% compared to the same period last year, while year-to-date revenue reached ¥1,464,947,132.50, up 8.97% year-on-year [4]. - Net profit attributable to shareholders for Q3 2023 was ¥89,203,600.05, representing a 29.14% increase year-on-year, and year-to-date net profit was ¥286,865,191.49, up 40.65% [4]. - The basic earnings per share for Q3 2023 was ¥0.1272, a 12.07% increase compared to the same period last year, with year-to-date diluted earnings per share also at ¥0.4090, up 22.05% [4]. - Total operating revenue for the current period reached CNY 1,464,947,132.50, an increase of 8.95% compared to CNY 1,344,402,602.13 in the previous period [20]. - Net profit for the current period was CNY 292,583,698.54, representing a 36.24% increase from CNY 214,596,952.02 in the previous period [21]. - Earnings per share (EPS) increased to CNY 0.4090 from CNY 0.3351, marking a growth of 22.05% [22]. Assets and Liabilities - The company's total assets at the end of Q3 2023 were ¥3,543,470,789.72, a decrease of 2.63% from the end of the previous year [4]. - The company’s equity attributable to shareholders at the end of Q3 2023 was ¥2,667,380,677.87, a decrease of 1.35% from the end of the previous year [4]. - The total liabilities decreased to CNY 830,182,267.56 from CNY 879,192,754.90, a reduction of 5.57% [22]. - The total equity attributable to shareholders of the parent company was CNY 2,667,380,677.87, down from CNY 2,703,749,664.26, a decline of 1.34% [22]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥223,951,981.61, an increase of 15.50% compared to the same period last year [4]. - The net cash inflow from operating activities was CNY 223.95 million, an increase of CNY 30.05 million or 15.50% year-on-year [11]. - The net cash outflow from investing activities was CNY 115.15 million, an increase of CNY 52.45 million or 83.66% year-on-year, primarily due to reduced cash inflow from financial product investments and increased long-term asset investments [11]. - The net cash outflow from financing activities was CNY 170.68 million, an increase of CNY 4.61 million or 2.78% year-on-year, mainly due to increased dividend distribution and short-term borrowings [11]. - The cash inflow from operating activities totaled CNY 1,634,268,265.69, compared to CNY 1,358,686,568.10, indicating an increase of 20.24% [23]. - The cash outflow for debt repayment was CNY 204,830,690.32, a decrease of 7.7% from CNY 222,000,000.00 in the same quarter last year [24]. Investments and Expenses - The company reported a significant increase in construction in progress, which rose to ¥149,094,700, an increase of 91.01% due to ongoing investments in smart traditional Chinese medicine production base and new pharmaceutical industrialization projects [8]. - Research and development expenses rose to CNY 58,183,284.31, up from CNY 50,502,876.94, reflecting a growth of 15.24% [20]. - The company experienced a 46.13% decline in revenue from formula granules, totaling ¥27,513,000, due to ongoing registration processes with national and provincial standards [9]. - The company recorded a significant increase in interest income, reaching CNY 17,342,268.01 compared to CNY 1,791,225.26 in the previous period [21]. Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 40,247 [13]. - The largest shareholder, Yu Youqiang, holds 18.52% of the shares, with 129,890,463 shares pledged [13]. Other Information - The company did not undergo an audit for the Q3 report [25]. - The report was issued by the board of directors on October 20, 2023 [26].